Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-07-26Clinical Trial Update: Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years [Phase 1]
Phase 1 pharmacokinetics and safety study of Sancuso (granisetron transdermal) and IV granisetron in children aged 6 to 12 with chemotherapy…
-
CLINICAL_TRIALS withdrawal · 2024-07-26Clinical Trial Update: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years [Phase 1]
A Phase 1 safety and pharmacokinetic assessment of Sancuso (granisetron) and IV granisetron in children aged 2 to 5 years for chemotherapy-i…
-
FDA approval · 2024-07-08FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for a generic ondansetron hydrochloride product submitted by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years [Phase 1]
Phase 1 study evaluating the safety and pharmacokinetics of the transdermal Sancuso and intravenous granisetron in adolescents (ages 13-17) …
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV) [Phase 3]
A Phase 3 clinical trial evaluating the safety and effectiveness of a granisetron transdermal patch for chemotherapy-induced nausea and vomi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients [NA]
A completed clinical trial from Indonesia University evaluated whether ear acupuncture can prevent chemotherapy-induced nausea and vomiting …
-
FDA approval · 2024-05-17FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
FDA approved a supplemental application for dronabinol from Wellhouse Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Use of Aromatherapy to Reduce Symptom Burden [Phase 2]
Phase 2 clinical trial evaluated aromatherapy to reduce symptom burden in patients with anxiety and chemotherapy-induced nausea and vomiting…
-
CLINICAL_TRIALS research · 2024-05-16Clinical Trial Update: Serious Gaming for Chemotherapy-induced Nausea and Vomiting [NA]
A clinical trial update indicates a recruiting study at the University of Central Florida evaluating serious gaming as an intervention for c…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer [Phase 3]
Phase 3 clinical trial investigating electroacupuncture plus a four-drug antiemetic regimen (including olanzapine) for chemotherapy-induced …
-
FDA approval · 2024-03-05FDA Approved: APONVIE — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for APONVIE (aprepitant) from Heron Therapeutics, Inc., expanding its regulatory authorization.
-
FDA approval · 2024-03-05FDA Approved: CINVANTI — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for CINVANTI (aprepitant) submitted by Heron Therapeutics, Inc.
-
FDA approval · 2024-01-31FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc., indicating an approved change to the generic's la…
-
FDA approval · 2024-01-05FDA Approved: DEXAMETHASONE INTENSOL — Supplemental Application (Hikma Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for DEXAMETHASONE INTENSOL from Hikma Pharmaceuticals USA, Inc., a dexamethasone product.
-
FDA approval · 2023-12-14FDA Approved: DRONABINOL — Supplemental Application (Camber Pharmaceuticals Inc)
FDA approved a supplemental application for dronabinol from Camber Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer [Phase 3]
Phase 3 trial investigating thalidomide for chemotherapy-related nausea and vomiting in pancreatic cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Low Dose Aprepitant for Patients Receiving Carboplatin [Phase 2]
Phase 2 trial investigating low-dose aprepitant for chemotherapy-induced nausea and vomiting in patients receiving carboplatin has been term…
-
FDA approval · 2023-10-12FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Granisetron Hydrochloride by Bionpharma Inc., a generic antiemetic used to prevent chemotherapy-…
-
FDA approval · 2023-10-10FDA Approved: FOSAPREPITANT DIMEGLUMINE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for fosaprepitant dimeglumine (generic) from Eugia US LLC under ANDA210625.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy [Phase 2]
A Phase 2 clinical trial update focused on preventing breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately…
-
FDA approval · 2023-09-26FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
FDA granted a supplemental approval for Ondansetron hydrochloride from Eugia US LLC, updating the status of this generic product. The action…
-
FDA approval · 2023-08-29FDA Approved: FOSAPREPITANT — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for Fosaprepitant, filed by Fresenius Kabi USA, expanding its approved labeling.
-
FDA approval · 2023-08-25FDA Approved: PALONOSETRON — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Palonosetron hydrochloride from Apotex Corp., confirming its generic use. Palonosetron is used t…
-
FDA approval · 2023-08-22FDA Approved: FOCINVEZ — Original Application (Steriscience Specialties Private Limited)
FDA approved FOCINVEZ (fosaprepitant dimeglumine) from Steriscience Specialties Private Limited through an Original Application for preventi…
-
CLINICAL_TRIALS research · 2023-08-18Clinical Trial Update: Observational Study on the Use of Akynzeo® in Patients Receiving HEC
An observational study update on the use of Akynzeo in patients receiving high-emetogenic chemotherapy (HEC) for chemotherapy-induced nausea…